Ampio Pharmaceuticals Inc (NYSEAMERICAN:AMPE) showcased the safety of intravenous (IV) Ampion in patients suffering from coronavirus during Phase 1 clinical study. Ampio conducted a controlled and randomized clinical study of IV Ampion in hospitalized patients with severe coronavirus. It evaluated the primary endpoint of the vaccine after a 5-day treatment […]